Drugs / Glycated Chitosan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03202446 | Jun 2016 → Jan 2018 | female breast carcinoma | Eske Corporation S.A.C | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glycated Chitosan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03202446 ↗ |
| Action | Activate | “designed to activate antigen presenting cells” NCT03202446 ↗ |
| Route | Other | “will be injected 1 mL of 1% Glycated Chitosan (GC) Injection” NCT03202446 ↗ |